| See why patients and professionals rely on this rFVIIa treatment. |
View online |
|
|
|
 |
| NovoSeven® RT is indicated for congenital hemophilia A or B with inhibitors, congenital Factor VII deficiency, Glanzmann’s thrombasthenia with refractoriness to platelets, and acquired hemophilia. |
|
|
|
| Success Speaks for Itself | Pharmacy Series |
 |
When my patient's life was in danger, I knew I could turn to my pharmacist for support.”1 |
|
| The #1 prescribed bypassing agent used in hospital pharmacies2,a |
| In situations where a patient does not bring their own clotting factor concentrate, MASAC recommends emergency departments have ready access to it within 1 hour upon a patient’s arrival.3 |
|
 |
For 30+ years, NovoSeven® RT has provided fast and trusted bleed control for even the most life-threatening bleeds.4,5,b,c |
|
 |
NovoSeven® RT covers the broadest range of patients with bleeding disorders (CHAwI or CHBwI, AH, CFVIId, and GT), compared to FEIBA®, OBIZUR®, and SevenFACT®.6-9,d |
|
 |
| NovoSeven® RT is designed for efficiency in pharmacies: |
| • |
Low-volume dosing and compact packaging6 |
| • |
16x less infusion volume compared to pd-aPCC6,7,c,e |
| • |
Room temperature storage up to 77°F6,f |
|
|
|
|
aCurrent as of July 13, 2022.
bIn compassionate use situations including surgery, central nervous system hemorrhages, severe intra-abdominal bleeding, and other life-threatening bleeding episodes.
cIn patients with hemophilia A or B with inhibitors.
dIndicated for bleed control and surgery in 4 bleeding disorders: CHAwI or CHBwI, AH, CFVIId, and GT.6
eIndividual doses for a joint bleed are compared and based on an 88-kg (194-lb) person.
fPrior to reconstitution, store NovoSeven® RT powder and histidine diluent between 36-77°F. After reconstitution, store NovoSeven® RT either at room temperature or refrigerated for up to 3 hours. Do not freeze reconstituted NovoSeven® RT or store in syringes.
|
| Scroll to see how NovoSeven® RT continues to support your patients. |
|
|
|
| Selected Important Safety Information |
| WARNING: THROMBOSIS |
| • |
Serious arterial and venous thrombotic events following administration
of NovoSeven® RT have been reported
|
|
| • |
Discuss the risks and explain the signs and symptoms of thrombotic and
thromboembolic events to patients who will receive
NovoSeven® RT
|
|
| • |
Monitor patients for signs or symptoms of activation of the coagulation
system and for thrombosis
|
|
|
| Warnings and Precautions |
| • |
Serious arterial and venous thrombotic events have been reported in clinical trials
and postmarketing surveillance
|
|
| • |
Patients with congenital hemophilia receiving concomitant treatment with aPCCs
(activated prothrombin complex concentrates), older patients particularly with
acquired hemophilia and receiving other hemostatic agents, and patients with a
history of cardiac and vascular disease may have an increased risk of developing
thrombotic events
|
|
| Please click here or scroll below for additional Important Safety Information. |
|
|
|
| Effective treatment for a broad rangeg of bleeding disorders6,10 |
| Indications |
NovoSeven® RT6,h |
FEIBA®7,i |
OBIZUR®8,j |
SEVENFACT®9,k,l |
| Congenital hemophilia A with inhibitors |
 |
|
|
 |
| Congenital hemophilia B with inhibitors |
|
|
|
|
| Acquired hemophiliam |
|
|
|
|
| Congenital factor VII deficiency |
|
|
|
|
| Glanzmann's thrombasthenia |
|
|
|
|
| with refractoriness to platelet transfusions, with or without antibodies to platelets |
|
|
|
|
| NovoSeven® RT6,h |
FEIBA®7,i |
OBIZUR®8,j |
SEVENFACT®9,k,l |
|
| Congenital hemophilia A with inhibitors |
|
|
| Congenital hemophilia B with inhibitors |
|
|
| Acquired hemophiliam |
|
|
| Congenital factor VII deficiency |
|
|
| Glanzmann’s thrombasthenia with refractoriness to platelets transfusions, with or without antibodies to platelets |
|
|
|
|
= bleed treatment; |
|
|
= perioperative management |
|
| This chart is not intended to compare efficacy or safety. |
|
|
gAs compared to FEIBA, OBIZUR and SEVENFACT.
hNovoSeven® RT is a recombinant FVIIa.
iFEIBA is an activated prothrombin complex concentrate (aPCC).
jOBIZUR is a porcine sequence recombinant FVIII.
kSEVENFACT is a recombinant FVIIa.
lSEVENFACT is only indicated for adults and adolescents (12 years and older).
mAdults with acquired hemophilia. |
|
|
| Indications and Usage |
| NovoSeven® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for: |
| • |
Treatment of bleeding episodes and perioperative management in adults and children
with hemophilia A or B with inhibitors, congenital Factor VII (FVII)
deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet
transfusions, with or without antibodies to platelets
|
|
| • |
Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia |
|
|
|
| Have you created an account on novoMEDLINK™? |
 |
| Keep up with important information about treatments for rare bleeding disorders. |
| Receive the latest news about rare bleeding disorders from Novo Nordisk. |
| Download, order, and share educational materials for you and your patients. |
|
|
|
|
| Important Safety Information (cont’d) |
| Warnings and Precautions |
| • |
Hypersensitivity reactions, including anaphylaxis, can occur with
NovoSeven® RT. Patients with a known hypersensitivity to mouse,
hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions.
Discontinue infusion and administer appropriate treatment when hypersensitivity
reactions occur
|
|
| • |
Factor VII deficient patients should be monitored for prothrombin time (PT) and
factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level,
or PT is not corrected, or bleeding is not controlled after treatment with the
recommended doses, antibody formation may be suspected and analysis for antibodies
should be performed
|
|
| • |
Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct
correlation to achieving hemostasis
|
|
| Adverse Reactions |
| • |
The most common and serious adverse reactions in clinical trials are thrombotic
events. Thrombotic adverse reactions following the administration of
NovoSeven® RT in clinical trials occurred in 4% of patients with
acquired hemophilia and 0.2% of bleeding episodes in patients with congenital
hemophilia
|
|
| Drug Interactions |
| • |
Thrombosis may occur if NovoSeven® RT is administered
concomitantly with Coagulation Factor XIII
|
|
|
Please click here for
Prescribing Information, including boxed Warning.
|
|
|
| 1. |
Data on file as of 2020. Novo Nordisk, Inc; Plainsboro, NJ. |
| 2. |
Data on file as of 2021. Novo Nordisk, Inc; Plainsboro, NJ. |
| 3. |
National Hemophilia Foundation. MASAC guidelines for emergency department management of individuals with hemophilia and other bleeding disorders, #257. 2019. |
| 4. |
Hedner U. History of rFVIIa therapy. Thromb Res. 2010;125:S4-S6. |
| 5. |
Lusher JM, Roberts HR, Davignon G, et al; and rFVIIa Study Group. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia. 1998;4(6):790-798. |
| 6. |
NovoSeven RT [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2020. |
| 7. |
FEIBA [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2020. |
| 8. |
OBIZUR [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2020. |
| 9. |
SEVENFACT [package insert]. Louisville, KY: HEMA Biologics; 2020. |
| 10. |
Bysted BV, Scharling B, Moller T, Hansen BL. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25°C stable formulation. Haemophilia. 2007;13(5): 527-532. |
|
|
<%@ include view='hcpColoradoFooter' %>
|
| Please do not respond to this email. If you would like to contact us, please click here or call 1-800-727-6500. |
| UNSUBSCRIBE NOTICE |
| If you no longer want to receive communications from Novo Nordisk, click here to unsubscribe. You also may call us at 1-877-744-2579 or send us a letter that includes your full contact information (eg, name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see our Privacy Statement. |
|
NovoSeven® is a registered trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
© 2022 Novo Nordisk All rights reserved. US22NSVN00059 August 2022 |
 |
|
|
|
